Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Platelet-activating factor activates mitogen-activated protein kinases, inhibits proliferation, induces differentiation and suppresses the malignant phenotype of human colon carcinoma cells

Oncogene volume 22, pages 2186–2191 (2003)Cite this article

Abstract

Recent studies suggest that the action of platelet-activating factor (PAF), a potent phospholipid modulator of allergic and inflammatory reactions, is diverse and functions as a modulator of a variety of physiological and pathological events in many cell types and tissues. Its role (if any) in modulating the proliferation, transformation and/or differentiation of epithelial colonic cells, however, is not known. In this study, we showed that PAF is biologically active in epithelial-derived human colon carcinoma cells with different phenotypic properties. These cells expressed the PAF receptor. PAF activated three prominent mitogen-activated protein kinase modules (ERK, p38MAPK and Jun N-terminal kinases) in these cells, inhibited proliferation and induced differentiation (measured by the induction of Waf1/p21 and the induction of the differentiation-related marker CEA). The net effect of PAF treatment was the suppression of malignant cell behavior (measured by anchorage-independent growth and cellular invasion). It is concluded that PAF is a modulator of proliferation and differentiation in human epithelial-derived colon carcinoma cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Bazan HE and Tao Y . (1997). J. Ocular Pharm. Ther., 13, 277–285.

  • Brattain MG, Levine AE, Chakrabarty S, Yeoman LC, Willson JKV and Long B . (1984). Cancer Met. Rev., 3, 177–191.

  • Chakrabarty S, Rajagopal S and Moskal TL . (1998). Lab. Invest., 78, 413–421.

  • Chakrabarty S, Tobon A, Varani J and Brattain MG . (1988). Cancer Res., 48, 4059–4064.

  • Di Cunto F, Topley G, Calautti E, Hsiao J, Ong L, Seth PK and Dotto GP . (1998). Science, 280, 1069–1072.

  • Guadagni F, Witt PL, Robbins PF, Schlom J and Greiner JW . (1990). Cancer Res., 50, 6248–6255.

  • Honda Z, Takano T, Gotoh Y, Nishida E, Ito K and Shimizu T . (1994). J. Biol. Chem., 269, 2307–2315.

  • Huang S, Trujillo JM and Chakrabarty S . (1992). Int. J. Cancer, 52, 978–986.

  • Kume K and Shimizu T . (1997). J. Biol. Chem., 272, 22898–22904.

  • Kunz D, Gerard NP and Gerard C . (1992) J. Biol. Chem., 267, 9101–9106.

  • Marques SA, Dy LC, Southall MD, Yi Q, Smietana E, Kapur R, Marques M, Travers JB and Spandau DF . (2002). J. Pharam. Exp. Ther., 300, 1026–1035.

  • Mukherjee P, DeCoster MA, Campbell FZ, Davis RJ and Bazan NG . (1999). J. Biol. Chem., 274, 6493–6498.

  • Prescott SM, Zimmerman GA, Stafforini DM and McIntyre TM . (2000). Ann. Rev. Biochem., 69, 419–445.

  • Reynolds S, Cederberg H and Chakrabarty S . (2000). Clin. Exp. Metastasis, 18, 309–312.

  • Reynolds S, Rajagopal S and Chakrabarty S . (1998). Cancer Lett., 134, 53–60.

  • Saito H, Hayakawa T, Mita H, Akiyama K and Shida T . (1992) J. Lipid Mediators, 5, 135–137.

  • Schaeffer HJ and Weber MJ . (1999). Mol. Cell. Biol., 19, 2435–2444.

  • Schroy, P . (1994). J. Cell. Physiol., 161, 111–123.

  • Shimada A, Ota Y, Sugiyama Y, Sato S, Kume K, Shimizu T and Inoue S . (1998). J. Invest. Dermatol., 110, 889–893.

  • Smith CS and Shearer WT . (1994). Cell. Immunol., 155, 292–303.

  • Sperber K, Shim J, Mehra M, Lin A, George I, Ogata S, Mayer L and Itzkowitz S . (1998). Inflamm. Bowel Dis., 4, 12–17.

  • Stoll LL, Yerram NR and Spector AA . (1991). J. Cell Sci., 100, 145–152.

  • Sugano T, Narashara H, Nasu K, Arima K, Fujisawa K and Miyakawa I . (2001). Mol. Hum. Reproduction, 7, 475–481.

  • Tokutomi T, Maruiwa H, Hirohata M, Miyagi T and Shigemori M . (2001). Neurol. Res., 23, 605–611.

  • Wang H, Chakrabarty S . (2001). J. Cell. Physiol., 187, 188–195.

  • Wang H, Rajagopal S, Reynolds S, Cederberg H and Chakrabarty S . (1999). J. Cell. Physiol., 178, 173–178.

Download references

Author information

Authors and Affiliations

  1. Division of Pathology and Laboratory Medicine, Department of Molecular Pathology, The University of Texas, M.D. Anderson Cancer Center, Houston, 77030, TX, USA

    Hongmei Wang & Subhas Chakrabarty

Authors
  1. Hongmei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Subhas Chakrabarty
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, H., Chakrabarty, S. Platelet-activating factor activates mitogen-activated protein kinases, inhibits proliferation, induces differentiation and suppresses the malignant phenotype of human colon carcinoma cells. Oncogene 22, 2186–2191 (2003). https://doi.org/10.1038/sj.onc.1206348

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206348

Keywords

This article is cited by

Search

Advanced search

Quick links